Mode
Text Size
Log in / Sign up
Phase 4 N=40 Randomized Triple-blind Treatment

Dexmedetomidine and Propofol for Pediatric MRI Sedation

Headache · Tumor · Seizure Disorder · Neurofibromatoses · Hydrocephalus

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion — 98; 77 minutes

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
propofol (Drug); Dexmedetomidine (Drug); Glycopyrrolate (Drug); Lidocaine 1% Injectable Solution (Drug); Nitrous Oxide (Drug); Sevoflurane (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Medical College of Wisconsin
Primary completion
Aug 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion
98; 77
SECONDARY
Total Propofol Administered
10.6; 3.0
SECONDARY
Dexmedetomidine Dose
0; 0.70
SECONDARY
Glycopyrrolate Dose
0; 4.2
SECONDARY
Lidocaine Dose
1.00; 1.00
SECONDARY
Nitrous Oxide
18; 17
SECONDARY
Sevoflurane
18; 17
SECONDARY
Eye Opening
28; 3
SECONDARY
Oral/Enteral Intake
33; 14
SECONDARY
Discharge Ready
40; 17
SECONDARY
Sleep Pattern
3; 2
SECONDARY
Irritability
3; 0
SECONDARY
Delirium
0; 0

Summary

The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). The drugs used for the MRI scan in this study will be chosen randomly. Half the patients will receive small doses of propofol and dexmedetomidine. The other half will receive propofol administered constantly throughout the scan. Other drugs that may be used include sevoflurane and nitrous oxide at the start of the sedation (for placing an intravenous), lidocaine (to reduce the pain of propofol injection) and glycopyrrolate (to prevent the heart rate from decreasing too low. The investigators will record 5 additional blood pressures and heart rates. If additional medications are required to complete the scan, the investigators will administer whatever is necessary. At the end of the study, the investigators will have an observer record the time it takes for participants to spontaneously open eyes , to be able to drink liquids and/or eat and to behave as before the study. Also, it is very important that the investigators find out from participants about changes in behavior, or if eating or sleeping habits were unusual following completion of the study. For that reason, the investigators will call participants in a day or so following the MRI scan. The investigators expect to recruit 40 children between the ages of 12 and 72 months for the study and hope to have the study completed in December 2018.

Eligibility Criteria

Inclusion Criteria

  • All children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes.

Exclusion Criteria

  • Inpatient status, airway abnormalities, allergy to any study medications, eggs and soy, and mitochondrial disorders.
  • All subjects with any cardiac disease or history of cardiac arrhythmias will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03513757). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search